Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 2/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KIF11 | P52732 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | NOS3 | P29474 | 2/20 | 0.40 |
| ▸ | NOS1 | P29475 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5065165 | 0.83 | BCL2L1 (0.53) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL11314219 | 0.76 | PTGS1 (0.54) | HSD17B1PTGS1MAPTSMN1; SMN2KIF11 | |
| SCHEMBL10436026 | 0.76 | MAOB (0.55) | HSD17B1PTGS1MAPTSMN1; SMN2KIF11 | |
| SCHEMBL30747689 | 0.76 | MAOB (0.55) | HSD17B1PTGS1MAPTSMN1; SMN2KIF11 | |
| SCHEMBL6191307 | 0.76 | MAPT (0.62) | HSD17B1PTGS1MAPTSMN1; SMN2KIF11 | |
| SCHEMBL2555397 | 0.75 | MAPT (0.48) | HSD17B1PTGS1MAPTSMN1; SMN2KIF11 | |
| SCHEMBL2559215 | 0.75 | RARB (0.59) | HSD17B1PTGS1MAPTSMN1; SMN2KIF11 | |
| SCHEMBL13864591 | 0.75 | HSD17B1 (0.68) | HSD17B1PTGS1MAPTSMN1; SMN2KIF11 | |
| SCHEMBL22926305 | 0.75 | FASN (0.51) | HSD17B1PTGS1MAPTSMN1; SMN2KIF11 | |
| SCHEMBL10925015 | 0.75 | HSD17B1 (0.54) | HSD17B1PTGS1MAPTSMN1; SMN2KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7320982-B2 | Use of 4-substituted tetrahydropyridines for the manufacture of medicaments acting upon TGF-β 1 | SANOFI-AVENTIS (FR) | 2008-01-22 | — | — | US | disclosed |
| US-20070054931-A1 | PREPARATION OF BENZOYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES AND USE THEREOF | SANOFI-AVENTIS (FR) | 2007-03-08 | — | — | US | disclosed |
| US-7151107-B2 | Use of benzoylalkyl-1,2,3,6-tetrahydropyridines | SANOFI-AVENTIS (FR) | 2006-12-19 | — | — | US | disclosed |
| US-20050222187-A1 | Use of benzoylalkyl-1,2,3,6-tetrahydropyridines | SANOFI-AVENTIS (FR) | 2005-10-06 | — | — | US | disclosed |
| US-6936621-B2 | Use of benzoylalkyl-1,2,3,6-tetrahydropyridines | SANOFI-AVENTIS (FR) | 2005-08-30 | — | — | US | disclosed |
| US-20040157868-A1 | Use of 4-substituted tetrahydropyridines for the manufacture of medicaments acting upon TGF-beta 1 | SANOFI-AVENTIS (FR) | 2004-08-12 | — | — | US | disclosed |
| US-20040122032-A1 | Use of benzoylalkyl-1,2,3,6-tetrahydropyridines | SANOFI-AVENTIS (FR) | 2004-06-24 | — | — | US | disclosed |
| EP-0979079-B1 | USE OF TETRAHYDROPYRIDINE DERIVATIVES TO PREPARE MEDICINES FOR TREATING DISEASES CAUSING DEMYELINATION | SANOFI SYNTHELABO (FR) | 2004-06-16 | — | — | EP | disclosed |
| US-6693118-B2 | E.G., 1-(2-(6,7-METHYLENEDIOXYNAPHTH-2-YL)-ETHYL)-4-(3-TRIFLUOROMETHYLPHENYL)-1,2,3,6-TETRAHYDROPYRIDINE AND 1-2-(4-CYCLOHEXENYLPHENYL)-ETHYL)-4-(3-TRIFLUOROMETHYLPHENYL)-1,2,3,6 -TETRAHYDROPYRIDINE; apoptosis inhibition; treatment of graft rejection or of acute or chronic rheumatoid arthritis | SANOFI-SYNTHELABO (FR) | 2004-02-17 | — | — | US | disclosed |
| EP-1017385-B1 | USE OF 4-SUBSTITUTED TETRAHYDROPYRIDINES FOR MAKING MEDICINES ACTING ON TGF-beta 1 | SANOFI SYNTHELABO (FR) | 2003-07-16 | — | — | EP | disclosed |
| EP-0950053-B1 | NEW DERIVATIVES OF BENZOYLALKYL-1,2,3,6-TETRAHYDROPYRIDINS | SANOFI SYNTHELABO (FR) | 2003-06-11 | — | — | EP | disclosed |
| US-20020091143-A1 | Use of 4-substituted tetrahydropyridines for the manufacture of medicament s acting upon TGF-beta 1 | SANOFI-AVENTIS (FR) | 2002-07-11 | — | — | US | disclosed |
| US-6358965-B1 | THERAPY AND/OR PROPHYLAXIS OF DISEASES WHICH INVOLVE NEURONAL DEGENERATION BY ADMINISTERING BENZOYL-1,2,3,6-TETRAHYDROPYRIDINES COMPOUND | SANOFI-SYNTHELABO (FR) | 2002-03-19 | — | — | US | disclosed |
| EP-1017385-A1 | USE OF 4-SUBSTITUTED TETRAHYDROPYRIDINES FOR MAKING MEDICINES ACTING ON TGF-beta 1 | SANOFI-SYNTHELABO (FR) | 2000-07-12 | — | — | EP | disclosed |
| EP-0979079-A1 | USE OF TETRAHYDROPYRIDINE DERIVATIVES TO PREPARE MEDICINES FOR TREATING DISEASES CAUSING DEMYELINATION | SANOFI-SYNTHELABO (FR) | 2000-02-16 | — | — | EP | disclosed |
| EP-0950053-A1 | USE OF BENZOYLALKYL-1,2,3,6-TETRAHYDROPYRIDINS | SANOFI (FR) | 1999-10-20 | — | — | EP | disclosed |
| WO-1998053821-A1 | USE OF 4-SUBSTITUTED TETRAHYDROPYRIDINES FOR MAKING MEDICINES ACTING ON TGF-β1 | SANOFI-SYNTHELABO (FR) | 1998-12-03 | — | — | WO | disclosed |
| WO-1998048802-A1 | USE OF TETRAHYDROPYRIDINE DERIVATIVES TO PREPARE MEDICINES FOR TREATING DISEASES CAUSING DEMYELINATION | SANOFI-SYNTHELABO (FR) | 1998-11-05 | — | — | WO | disclosed |
| WO-1998028274-A1 | USE OF BENZOYLALKYL-1,2,3,6-TETRAHYDROPYRIDINS | SANOFI (FR) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091143-A1 | Use of 4-substituted tetrahydropyridines for the manufacture of medicament s acting upon TGF-beta 1 | TGFB1, TGFBR1, TGFB2 | HSD17B1 2993/4885PTGS1 25/4885MAPT 1010/4885 |
| US-20040122032-A1 | Use of benzoylalkyl-1,2,3,6-tetrahydropyridines | KCNH1, KCNJ2, CACNA1B | HSD17B1 2880/4885PTGS1 295/4885MAPT 388/4885 |
| US-20070054931-A1 | PREPARATION OF BENZOYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES AND USE THEREOF | BDNF, KCNH1, GABRA6 | HSD17B1 3557/4885PTGS1 290/4885MAPT 310/4885 |
| US-20050222187-A1 | Use of benzoylalkyl-1,2,3,6-tetrahydropyridines | KCNH1, ATP6V1B2, KCNJ6 | HSD17B1 3220/4885PTGS1 331/4885MAPT 296/4885 |
| US-20040157868-A1 | Use of 4-substituted tetrahydropyridines for the manufacture of medicaments acting upon TGF-beta 1 | TGFB1, TGFBR1, TGFB2 | HSD17B1 3004/4885PTGS1 26/4885MAPT 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.